{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T01:41:49Z","timestamp":1773106909327,"version":"3.50.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T00:00:00Z","timestamp":1742860800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T00:00:00Z","timestamp":1742860800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Pharmacol Sin"],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Multiple myeloma (MM) is a malignant hematological disease caused by the proliferation of abnormal plasma cells in the bone marrow and is still incurable. Relapse and drug resistance are common in MM. New therapeutic targets are urgently needed for MM treatment. Human antigen R (HuR) has been reported to play an important role in the malignant biological behavior of a variety of tumors, but its role in MM remains unclear. In this study, we found that HuR was highly expressed in MM patients and associated with a poor prognosis by analyzing public datasets. We found that targeting HuR with short hairpin RNA (shRNA) or its inhibitor CMLD-2 had significant anti-MM effects both in vitro and in vivo. The overexpression of HuR promotes MM cell proliferation in vitro and in vivo. Moreover, we demonstrated that bortezomib drug sensitivity increased and decreased with the knockdown and overexpression of HuR, respectively. This result provides a rationale for our subsequent combination of CMLD-2 with bortezomib in the treatment of MM. To further explore the mechanism of HuR in MM, we performed RNA sequencing and identified its downstream molecule, E2F7. HuR upregulated E2F7 expression by increasing the stability of its mRNA in MM cells. Higher levels of E2F7 were associated with a poorer prognosis. E2F7 knockdown had anti-MM effects in vitro and in vivo. E2F7 overexpression partially rescued the cell proliferation inhibition and apoptosis caused by targeting HuR in MM cells. We subsequently demonstrated that CMLD-2 synergized with the anti-MM effect of bortezomib both in vitro and in vivo. In conclusion, targeting the HuR\/E2F7 axis synergizes with bortezomib against MM. Therefore, the HuR\/E2F7 axis may serve as a promising therapeutic target for MM.<\/jats:p>","DOI":"10.1038\/s41401-025-01529-3","type":"journal-article","created":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T10:51:36Z","timestamp":1742899896000},"page":"2296-2309","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Targeting the HuR\/E2F7 axis synergizes with bortezomib against multiple myeloma"],"prefix":"10.1038","volume":"46","author":[{"given":"Ming-yuan","family":"Jia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ze","family":"Fu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen-bin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheng-yu","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin-yi","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying-li","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hua","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,3,25]]},"reference":[{"key":"1529_CR1","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1002\/ajh.27422","volume":"99","author":"SV Rajkumar","year":"2024","unstructured":"Rajkumar SV. Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management. Am J Hematol. 2024;99:1802\u201324.","journal-title":"Am J Hematol"},{"key":"1529_CR2","doi-asserted-by":"publisher","first-page":"e670","DOI":"10.1016\/S2352-3026(22)00165-X","volume":"9","author":"J Huang","year":"2022","unstructured":"Huang J, Chan SC, Lok V, Zhang L, Lucero-Prisno DE 3rd, et al. The epidemiological landscape of multiple myeloma: a global cancer registry estimate of disease burden, risk factors, and temporal trends. Lancet Haematol. 2022;9:e670\u2013e7.","journal-title":"Lancet Haematol"},{"key":"1529_CR3","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1056\/NEJMoa2312054","volume":"390","author":"P Sonneveld","year":"2024","unstructured":"Sonneveld P, Dimopoulos MA, Boccadoro M, Quach H, Ho PJ, Beksac M, et al. Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2024;390:301\u201313.","journal-title":"N Engl J Med"},{"key":"1529_CR4","doi-asserted-by":"publisher","first-page":"604","DOI":"10.3324\/haematol.2023.283073","volume":"109","author":"T Facon","year":"2024","unstructured":"Facon T, Moreau P, Baker R, Min CK, Leleu X, Mohty M, et al. Isatuximab plus carfilzomib and dexamethasone in patients with early versus late relapsed multiple myeloma: IKEMA subgroup analysis. Haematologica. 2024;109:604\u201316.","journal-title":"Haematologica"},{"key":"1529_CR5","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1056\/NEJMoa2209900","volume":"387","author":"S Mailankody","year":"2022","unstructured":"Mailankody S, Devlin SM, Landa J, Nath K, Diamonte C, Carstens EJ, et al. GPRC5D-targeted CAR T cells for myeloma. N Engl J Med. 2022;387:1196\u2013206.","journal-title":"N Engl J Med"},{"key":"1529_CR6","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s13045-020-00962-7","volume":"13","author":"B Yu","year":"2020","unstructured":"Yu B, Jiang T, Liu D. BCMA-targeted immunotherapy for multiple myeloma. J Hematol Oncol. 2020;13:125.","journal-title":"J Hematol Oncol"},{"key":"1529_CR7","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.trecan.2017.05.003","volume":"3","author":"B Pereira","year":"2017","unstructured":"Pereira B, Billaud M, Almeida R. RNA-binding proteins in cancer: old players and new actors. Trends Cancer. 2017;3:506\u201328.","journal-title":"Trends Cancer"},{"key":"1529_CR8","doi-asserted-by":"publisher","first-page":"3848","DOI":"10.1172\/JCI130379","volume":"130","author":"M Palomo-Irigoyen","year":"2020","unstructured":"Palomo-Irigoyen M, P\u00e9rez-Andr\u00e9s E, Iruarrizaga-Lejarreta M, Barreira-Manrique A, Tamayo-Caro M, Vila-Vecilla L, et al. HuR\/ELAVL1 drives malignant peripheral nerve sheath tumor growth and metastasis. J Clin Invest. 2020;130:3848\u201364.","journal-title":"J Clin Invest"},{"key":"1529_CR9","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1007\/s00403-020-02051-8","volume":"312","author":"H Zhou","year":"2020","unstructured":"Zhou H, Rao Y, Sun Q, Liu Y, Zhou X, Chen Y, et al. MiR-4458\/human antigen R (HuR) modulates PBX3 mRNA stability in melanoma tumorigenesis. Arch Dermatol Res. 2020;312:665\u201373.","journal-title":"Arch Dermatol Res"},{"key":"1529_CR10","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1080\/15384047.2022.2034455","volume":"23","author":"HHC-M Xiao","year":"2022","unstructured":"Xiao HHC-M, Ye X, Vishwakarma V, Preet R, Dixon DA. CRC-derived exosomes containing the RNA binding protein HuR promote lung cell proliferation by stabilizing c-Myc mRNA. Cancer Biol Ther. 2022;23:139\u201349.","journal-title":"Cancer Biol Ther"},{"key":"1529_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.939784","volume":"12","author":"Z Cai","year":"2022","unstructured":"Cai Z, Xu H, Bai G, Hu H, Wang D, Li H, et al. ELAVL1 promotes prostate cancer progression by interacting with other m6A regulators. Front Oncol. 2022;12:939784.","journal-title":"Front Oncol"},{"key":"1529_CR12","doi-asserted-by":"publisher","first-page":"2446","DOI":"10.1111\/cas.13657","volume":"109","author":"R Zhang","year":"2018","unstructured":"Zhang R, Wang J. HuR stabilizes TFAM mRNA in an ATM\/p38-dependent manner in ionizing irradiated cancer cells. Cancer Sci. 2018;109:2446\u201357.","journal-title":"Cancer Sci"},{"key":"1529_CR13","doi-asserted-by":"publisher","first-page":"1962","DOI":"10.1002\/1878-0261.13478","volume":"17","author":"L Wei","year":"2023","unstructured":"Wei L, Zhang Q, Zhong C, He L, Zhang Y, Armaly AM, et al. Functional inhibition of the RNA-binding protein HuR sensitizes triple-negative breast cancer to chemotherapy. Mol Oncol. 2023;17:1962\u201380.","journal-title":"Mol Oncol"},{"key":"1529_CR14","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1186\/s13578-023-01137-w","volume":"13","author":"Q Zhang","year":"2023","unstructured":"Zhang Q, Yang Z, Hao X, Dandreo LJ, He L, Zhang Y, et al. Niclosamide improves cancer immunotherapy by modulating RNA-binding protein HuR-mediated PD-L1 signaling. Cell Biosci. 2023;13:192.","journal-title":"Cell Biosci"},{"key":"1529_CR15","doi-asserted-by":"crossref","unstructured":"Morillo-Bernal J, Pizarro-Garc\u00eda P, Moreno-Bueno G, Cano A, Maz\u00f3n MJ, Eraso P, et al. HuR (ELAVL1) stabilizes SOX9 mRNA and promotes migration and invasion in breast cancer cells. Cancers. 2024;16:384.","DOI":"10.3390\/cancers16020384"},{"key":"1529_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-43894-0","volume":"9","author":"L Allegri","year":"2019","unstructured":"Allegri L, Baldan F, Roy S, Aube J, Russo D, Filetti S, et al. The HuR CMLD-2 inhibitor exhibits antitumor effects via MAD2 downregulation in thyroid cancer cells. Sci Rep. 2019;9:7374.","journal-title":"Sci Rep"},{"key":"1529_CR17","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1158\/1535-7163.MCT-18-0945","volume":"18","author":"J Cai","year":"2019","unstructured":"Cai J, Wang H, Jiao X, Huang R, Qin Q, Zhang J, et al. The RNA-binding protein HuR confers oxaliplatin resistance of colorectal cancer by upregulating CDC6. Mol Cancer Ther. 2019;18:1243\u201354.","journal-title":"Mol Cancer Ther"},{"key":"1529_CR18","doi-asserted-by":"publisher","first-page":"87","DOI":"10.4143\/crt.2009.41.2.87","volume":"41","author":"SJ Lim","year":"2009","unstructured":"Lim SJ, Lee SH, Joo SH, Song JY, Choi SI. Cytoplasmic expression of HuR is related to cyclooxygenase-2 expression in colon cancer. Cancer Res Treat. 2009;41:87\u201392.","journal-title":"Cancer Res Treat"},{"key":"1529_CR19","doi-asserted-by":"publisher","first-page":"2529","DOI":"10.1038\/onc.2015.325","volume":"35","author":"FF Blanco","year":"2016","unstructured":"Blanco FF, Jimbo M, Wulfkuhle J, Gallagher I, Deng J, Enyenihi L, et al. The mRNA-binding protein HuR promotes hypoxia-induced chemoresistance through posttranscriptional regulation of the proto-oncogene PIM1 in pancreatic cancer cells. Oncogene. 2016;35:2529\u201341.","journal-title":"Oncogene"},{"key":"1529_CR20","doi-asserted-by":"publisher","first-page":"4460","DOI":"10.1158\/0008-5472.CAN-17-0015","volume":"77","author":"M Zarei","year":"2017","unstructured":"Zarei M, Lal S, Parker SJ, Nevler A, Vaziri-Gohar A, Dukleska K, et al. Posttranscriptional upregulation of IDH1 by HuR establishes a powerful survival phenotype in pancreatic cancer cells. Cancer Res. 2017;77:4460\u201371.","journal-title":"Cancer Res"},{"key":"1529_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-49874-x","volume":"15","author":"D Adamoski","year":"2024","unstructured":"Adamoski D, M Dos Reis L, Mafra ACP, Corr\u00eaa-da-Silva F, Moraes-Vieira PMM, Berindan-Neagoe I, et al. HuR controls glutaminase RNA metabolism. Nat Commun. 2024;15:5620.","journal-title":"Nat Commun"},{"key":"1529_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.109178","volume":"35","author":"K Rothamel","year":"2021","unstructured":"Rothamel K, Arcos S, Kim B, Reasoner C, Lisy S, Mukherjee N, et al. ELAVL1 primarily couples mRNA stability with the 3\u2019 UTRs of interferon-stimulated genes. Cell Rep. 2021;35:109178.","journal-title":"Cell Rep"},{"key":"1529_CR23","doi-asserted-by":"publisher","first-page":"2987","DOI":"10.1073\/pnas.0306453101","volume":"101","author":"I L\u00f3pez de Silanes","year":"2004","unstructured":"L\u00f3pez de Silanes I, Zhan M, Lal A, Yang X, Gorospe M. Identification of a target RNA motif for RNA-binding protein HuR. Proc Natl Acad Sci USA. 2004;101:2987\u201392.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1529_CR24","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1007\/PL00000854","volume":"58","author":"CM Brennan","year":"2001","unstructured":"Brennan CM, Steitz JA. HuR and mRNA stability. Cell Mol Life Sci. 2001;58:266\u201377.","journal-title":"Cell Mol Life Sci"},{"key":"1529_CR25","doi-asserted-by":"publisher","first-page":"6289","DOI":"10.1093\/emboj\/cdg613","volume":"22","author":"L Di Stefano","year":"2003","unstructured":"Di Stefano L, Jensen MR, Helin K. E2F7, a novel E2F featuring DP-independent repression of a subset of E2F-regulated genes. Embo J. 2003;22:6289\u201398.","journal-title":"Embo J"},{"key":"1529_CR26","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1038\/s41388-018-0494-7","volume":"38","author":"S Xiang","year":"2019","unstructured":"Xiang S, Wang Z, Ye Y, Zhang F, Li H, Yang Y, et al. E2F1 and E2F7 differentially regulate KPNA2 to promote the development of gallbladder cancer. Oncogene. 2019;38:1269\u201381.","journal-title":"Oncogene"},{"key":"1529_CR27","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s13005-021-00258-2","volume":"17","author":"P Zhou","year":"2021","unstructured":"Zhou P, Xiao L, Xu X. Identification of E2F transcription factor 7 as a novel potential biomarker for oral squamous cell carcinoma. Head Face Med. 2021;17:7.","journal-title":"Head Face Med"},{"key":"1529_CR28","doi-asserted-by":"publisher","first-page":"2323","DOI":"10.1111\/ajt.17124","volume":"22","author":"S Ling","year":"2022","unstructured":"Ling S, Zhan Q, Jiang G, Shan Q, Yin L, Wang R, et al. E2F7 promotes mammalian target of rapamycin inhibitor resistance in hepatocellular carcinoma after liver transplantation. Am J Transplant. 2022;22:2323\u201336.","journal-title":"Am J Transplant"},{"key":"1529_CR29","doi-asserted-by":"publisher","first-page":"849","DOI":"10.3892\/or.2020.7659","volume":"44","author":"Y Wang","year":"2020","unstructured":"Wang Y, Pei X, Xu P, Tan Z, Zhu Z, Zhang G, et al. E2F7, regulated by miR\u201130c, inhibits apoptosis and promotes cell cycle of prostate cancer cells. Oncol Rep. 2020;44:849\u201362.","journal-title":"Oncol Rep."},{"key":"1529_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-018-0444-x","volume":"9","author":"YY Ye","year":"2018","unstructured":"Ye YY, Mei JW, Xiang SS, Li HF, Ma Q, Song XL, et al. MicroRNA-30a-5p inhibits gallbladder cancer cell proliferation, migration and metastasis by targeting E2F7. Cell Death Dis. 2018;9:410.","journal-title":"Cell Death Dis"},{"key":"1529_CR31","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/j.csbj.2015.09.001","volume":"13","author":"B Yadav","year":"2015","unstructured":"Yadav B, Wennerberg K, Aittokallio T, Tang J. Searching for drug synergy in complex dose\u2013response landscapes using an interaction potency model. Comput Struct Biotechnol J. 2015;13:504\u201313.","journal-title":"Comput Struct Biotechnol J"},{"key":"1529_CR32","doi-asserted-by":"publisher","first-page":"20948","DOI":"10.1074\/jbc.M701751200","volume":"282","author":"EJ Fialcowitz-White","year":"2007","unstructured":"Fialcowitz-White EJ, Brewer BY, Ballin JD, Willis CD, Toth EA, Wilson GM. Specific protein domains mediate cooperative assembly of HuR oligomers on AU-rich mRNA-destabilizing sequences. J Biol Chem. 2007;282:20948\u201359.","journal-title":"J Biol Chem"},{"key":"1529_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2023.216486","volume":"580","author":"X Wang","year":"2024","unstructured":"Wang X, Xu J, Li Q, Zhang Y, Lin Z, Zhai X, et al. RNA-binding protein hnRNPU regulates multiple myeloma resistance to selinexor. Cancer Lett. 2024;580:216486.","journal-title":"Cancer Lett"},{"key":"1529_CR34","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.3324\/haematol.2019.218289","volume":"105","author":"J Tong","year":"2020","unstructured":"Tong J, Xu X, Zhang Z, Ma C, Xiang R, Liu J, et al. Hypoxia-induced long non-coding RNA DARS-AS1 regulates RBM39 stability to promote myeloma malignancy. Haematologica. 2020;105:1630\u201340.","journal-title":"Haematologica"},{"key":"1529_CR35","doi-asserted-by":"crossref","unstructured":"Zeng P, Wang F, Long X, Cao Y, Wen F, Li J, et al. CPEB2 enhances cell growth and angiogenesis by upregulating ARPC5 mRNA stability in multiple myeloma. J Orthop Surg Res. 2023;18:384.","DOI":"10.1186\/s13018-023-03835-0"},{"key":"1529_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2022.114442","volume":"188","author":"M Majumder","year":"2022","unstructured":"Majumder M, Chakraborty P, Mohan S, Mehrotra S, Palanisamy V. HuR as a molecular target for cancer therapeutics and immune-related disorders. Adv Drug Deliv Rev. 2022;188:114442.","journal-title":"Adv Drug Deliv Rev"},{"key":"1529_CR37","doi-asserted-by":"publisher","DOI":"10.1186\/1476-4598-11-13","volume":"11","author":"E Latorre","year":"2012","unstructured":"Latorre E, Tebaldi T, Viero G, Spart\u00e0 AM, Quattrone A, Provenzani A. Downregulation of HuR as a new mechanism of doxorubicin resistance in breast cancer cells. Mol Cancer. 2012;11:13.","journal-title":"Mol Cancer"},{"key":"1529_CR38","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-024-04970-w","volume":"22","author":"H You","year":"2024","unstructured":"You H, Song G, Xu Z, Chen S, Shen W, Liu H, et al. HuR promotes castration-resistant prostate cancer progression by altering ERK5 activation via posttranscriptional regulation of BCAT1. J Transl Med. 2024;22:178.","journal-title":"J Transl Med"},{"key":"1529_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2024.116458","volume":"227","author":"C Luo","year":"2024","unstructured":"Luo C, Chen G, Li R, Peng S, Zhang P, Wang F, et al. Juglone suppresses vasculogenic mimicry in glioma through inhibition of HuR-mediated VEGF-A expression. Biochem Pharmacol. 2024;227:116458.","journal-title":"Biochem Pharmacol"},{"key":"1529_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-024-06570-4","volume":"15","author":"C Tang","year":"2024","unstructured":"Tang C, Zhuang H, Wang W, Wang Q, Ma X, Wang B, et al. CircNUP54 promotes hepatocellular carcinoma progression via facilitating HuR cytoplasmic export and stabilizing BIRC3 mRNA. Cell Death Dis. 2024;15:191.","journal-title":"Cell Death Dis"},{"key":"1529_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e34362","volume":"10","author":"KQ Chen","year":"2024","unstructured":"Chen KQ, Lei HB, Liu X, Wang SZ. The roles of E2F7 in cancer: current knowledge and future prospects. Heliyon. 2024;10:e34362.","journal-title":"Heliyon"},{"key":"1529_CR42","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1002\/mc.23454","volume":"61","author":"F Hao","year":"2022","unstructured":"Hao F, Wang N, Zhang Y, Xu W, Chen Y, Fei X, et al. E2F7 enhances hepatocellular carcinoma growth by preserving the SP1\/SOX4\/Anillin axis via repressing miRNA-383-5p transcription. Mol Carcinog. 2022;61:975\u201388.","journal-title":"Mol Carcinog"},{"key":"1529_CR43","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1038\/s41416-020-01032-y","volume":"123","author":"R Yang","year":"2020","unstructured":"Yang R, Wang M, Zhang G, Bao Y, Wu Y, Li X, et al. E2F7-EZH2 axis regulates PTEN\/AKT\/mTOR signalling and glioblastoma progression. Br J Cancer. 2020;123:1445\u201355.","journal-title":"Br J Cancer"},{"key":"1529_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2017.188","volume":"8","author":"RF Xiang","year":"2017","unstructured":"Xiang RF, Wang Y, Zhang N, Xu WB, Cao Y, Tong J, et al. MK2206 enhances the cytocidal effects of bufalin in multiple myeloma by inhibiting the AKT\/mTOR pathway. Cell Death Dis. 2017;8:e2776.","journal-title":"Cell Death Dis"},{"key":"1529_CR45","doi-asserted-by":"publisher","first-page":"2565","DOI":"10.1080\/10428194.2022.2086247","volume":"63","author":"X Zeng","year":"2022","unstructured":"Zeng X, Xu W, Tong J, Liu J, Zhang Z, Liu M, et al. SPAG5 as a novel biomarker and potential therapeutic target via regulating AKT pathway in multiple myeloma. Leuk Lymphoma. 2022;63:2565\u201372.","journal-title":"Leuk Lymphoma"}],"container-title":["Acta Pharmacologica Sinica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41401-025-01529-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-025-01529-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-025-01529-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T09:58:28Z","timestamp":1757152708000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41401-025-01529-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,25]]},"references-count":45,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["1529"],"URL":"https:\/\/doi.org\/10.1038\/s41401-025-01529-3","relation":{},"ISSN":["1671-4083","1745-7254"],"issn-type":[{"value":"1671-4083","type":"print"},{"value":"1745-7254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,25]]},"assertion":[{"value":"10 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was approved by the Ruijin Hospital Ethics Committee of Shanghai JiaoTong University School of Medicine.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}